Surgery Websites
Colorectal Surgery »  Faculty »  Medical Oncology »  Emily Bergsland, M.D.
Emily Bergsland, M.D.

Emily Bergsland, M.D.

  • Professor of Clinical Medicine
  • Division of Hematology Oncology
  • Department of Medicine
  • Ernest Rosenbaum, MD Endowed Chair of Medical Oncology
Open Popup

UniversUniversity of Wisconsin, B.S., 1985, Biochemistry and Molecular Biology
University of Minnesota, M.D., 1982

  • 1989-92, Intern, Dept. of Medicine, University of California San Francisco
  • 1990-92, Resident, Dept. of Medicine, University of California San Francisco
  • 1992-92, Chief Resident and Assistant Chief of the Medical Service, Dept. of Medicine, University of California San Francisco
  • 1993-92, Fellow, Medical Oncology, University of California San Francisco
  • 1994-1992, Research Fellow (P I: Douglas Hanahan, Ph.D.), Department of Biochemistry and Biophysics, University of California San Francisco
  • American Board of Internal Medicine
  • American Board of Internal Medicine: Medical Oncology - Subspecialty
  • Angiogenesis Inhibitors
  • Colorectal Neoplasms
  • Neuroendocrine Tumors
  • Pancreatic Neoplasms
  • Vascular Endothelial Growth Factor

Dr. Emily Bergsland is currently a Professor of Clinical Medicine and holds the Ernest Rosenbaum, MD Endowed Chair of Medical Oncology. She received her medical degree from the University of Minnesota and completed an internship, residency, and chief residency in internal medicine at UCSF. She subsequently completed a fellowship in Medical Oncology and was a Molecular Medicine fellow before joining the UCSF faculty in 1998.

Dr. Bergsland has led numerous clinical studies in patients with gastrointestinal malignancies. Her current efforts are focused on clinical and translational research related to neuroendocrine tumors. At a national level, Dr. Bergsland is a member of the Neuroendocrine Tumor Task force for the National Cancer Institute and a member of the NCCN NET guidelines panel. She is also the study chair for a national study of a novel treatment for patients with carcinoid tumors performed by the ALLIANCE for Clinical Trials and funded by the National Cancer Institute.

Bergsland And Nakakura

Data provided by UCSF Profiles, powered by CTSI
  • UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology
    Sponsor:
    Sponsor ID:
    Funding Period:
    Jul 2021
    -
    Jun 2026
    Principal Investigator
Data provided by UCSF Profiles, powered by CTSI
MOST RECENT PUBLICATIONS FROM A TOTAL OF 140
Data provided by UCSF Profiles, powered by CTSI
  1. Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. Br J Cancer. 2023 May 19. View in PubMed
  2. Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovittz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA. Consensus recommendations for management of high grade neuroendocrine tumors. Endocr Relat Cancer. 2023 May 01. View in PubMed
  3. Wang SJ, Whitman J, Paciorek A, Le BK, Nakakura EK, Behr SC, Joseph N, Zhang L, Hope TA, Bergsland EK. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time. J Neuroendocrinol. 2023 Apr; 35(4):e13260. View in PubMed
  4. Le BK, McGarrah P, Paciorek A, Mohamed A, Apolo AB, Chan DL, Reidy-Lagunes D, Hauser H, Rivero JD, Whitman J, Batty K, Zhang L, Raj N, Le T, Bergsland E, Halfdanarson TR. Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review. Clin Genitourin Cancer. 2023 Mar 17. View in PubMed
  5. Das S, Phillips S, Lee CL, Agarwal R, Bergsland E, Strosberg J, Chan JA, LaFerriere H, Ramirez RA, Berlin J, Dasari A. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis. Eur J Cancer. 2023 Mar; 182:43-52. View in PubMed
  6. View All Publications

 

Site Directory
    X